Literature DB >> 9989959

Automated heparin-delivery system to control activated partial thromboplastin time: evaluation in normal volunteers.

C P Cannon1, J Dingemanse, C H Kleinbloesem, T Jannett, K M Curry, C P Valcke.   

Abstract

BACKGROUND: Unfractionated heparin is used widely; however, control of the level of anticoagulation remains its greatest problem, with fewer than 35% of patients having activated partial thromboplastin times (aPTTs) within a range of 55 to 85 seconds in recent trials. METHODS AND
RESULTS: We developed and tested a prototype of an automated heparin control system (AutoHep) in which a computer-based titration algorithm adjusted the heparin infusion to reach a target aPTT. In 1 study, 12 healthy male subjects received an intravenous infusion of heparin with the rate determined by AutoHep and were randomized to receive an initial bolus or no bolus of heparin preceding the infusion. A second study evaluated the automated blood sampling system in 12 subjects. Of the 344 end-point aPTT measurements, 78% were within +/-10 seconds of the target (prespecified primary end point), and 89% were within a +/-15-second range. The time to achieve a target aPTT was 93 minutes without and 150 minutes with an initial heparin bolus. The total percentage of time within the target range +/-15 seconds was 46 of 48 hours (96%). The automatic blood sampling system successfully obtained 96% of all scheduled samples.
CONCLUSIONS: These results suggest that the AutoHep system has the potential to significantly improve aPTT control of intravenous heparin compared with current clinical practice.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9989959     DOI: 10.1161/01.cir.99.6.751

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  3 in total

1.  An automated strategy for bedside aPTT determination and unfractionated heparin infusion adjustment in acute coronary syndromes: insights from PARAGON A.

Authors:  L Kristin Newby; Robert A Harrington; Manjushri V Bhapkar; Frans Van de Werf; Judith S Hochman; Christopher B Granger; R John Simes; Catherine G Davis; Eric J Topol; Robert M Califf; David J Moliterno
Journal:  J Thromb Thrombolysis       Date:  2002-08       Impact factor: 2.300

2.  Heparin requirements for full anticoagulation are higher for patients on dabigatran than for those on warfarin - a model-based study.

Authors:  Thomas Edrich; Gyorgy Frendl; Gregory Michaud; Ioannis Ch Paschalidis
Journal:  Clin Pharmacol       Date:  2015-02-05

3.  Pharmacokinetic/pharmacodynamic modeling for dose selection for the first-in-human trial of the activated Factor XII inhibitor garadacimab (CSL312).

Authors:  Dipti Pawaskar; Xi Chen; Fiona Glassman; Frauke May; Anthony Roberts; Mark Biondo; Andrew McKenzie; Marc W Nolte; William J Jusko; Michael Tortorici
Journal:  Clin Transl Sci       Date:  2021-12-08       Impact factor: 4.689

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.